Direct-to-Patient Survey Results Summary
Health Care, Innovation, Supply Chain
During the 2022 GCSG US conference in San Antonio, 65 attendees participated in our Direct-to-Patient (DtP) survey. While 2/3rd’s of the respondents represented pharmaceutical companies / sponsors, there is also a strong mix of input from service providers. Over 50% of participants also had experience with DtP. Though a need for technology improvements was noted, our industry’s adoption of patient centric services like DTP continues to boost the growth of decentralized trials.
Related Education Resources.
All ResourcesFDA Guidance on CT Mgmt during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
Understanding Blockchain and AI in the Clinical Supply Chain
Topics: Conference, Supply Chain
Video
Members
The Use of Direct-to-Patient Methods in Decentralized Clinical Trials in Israel
Topic: Direct-to-Patient
White Paper
Free
